Revium Rx

Revium Rx is an innovative biotechnology company pioneering next-generation, lipid-based therapies designed to overcome some of the most pressing challenges in modern medicine.

Biotechnology
Active
Pre-Funding Herzliya, Israel Founded 1997
Last updated 2026-09-06
Total raised
$5.3M
Stage
Pre-Funding
Founded
1997
Headcount
5
HQ
Herzliya, Israel
Sector
Biotechnology

About

Revium Rx is a preclinical biotechnology company developing next-generation, lipid-based therapies to address unmet medical needs in antimicrobial resistance and oncology. The company utilizes a novel drug delivery technology to develop encapsulated therapeutics for several therapeutic indications, including antibiotics for antimicrobial-resistant bacteria, a lipid-based adjuvant for solid carcinogenic tumors, and immunization. Revium Rx's technology integrates well-defined active substances with a proprietary, clinically proven drug-loading process to produce lipid-based particle carrier compositions. Their approach is inspired by the success of Doxil®, the first FDA-approved nano-drug for cancer treatment, and is guided by Professor Chezy Barenholz, one of the original innovators behind liposomal drug delivery.

Funding history · 2 rounds · $5.3M total

2 events/rounds · $5.3M Total Funding: $950K in Private Equity, $4.4M in Public Equity
Feb 2025
Follow-on PO $4.4M sec.gov ↗
★ LipoVation Ltd.★ Revium Recovery Inc.
Nov 2023
Undisclosed Round $950K sec.gov ↗
★ Third Eye Investors LLC★ Certain qualified investors

Headcount over time

5 employees (2026-09) · 1 point
5 5 2026-09

Offices

Herzliya, Israel · HQ / main office

Q&A

What is Revium Rx's primary focus?
Revium Rx develops advanced delivery systems for various indications, utilizing an advanced lipid-based platform to enhance encapsulated therapeutics for hard-to-treat diseases.
What therapeutic areas does Revium Rx's current pipeline address?
Revium Rx's current pipeline includes antibiotics for antimicrobial-resistant bacteria, immune checkpoint inhibitor adjuvants for solid tumors, and a novel immunization platform.
When was Revium Rx founded?
Revium Rx was founded in June 2021.
Where is Revium Rx headquartered?
Revium Rx is headquartered in Herzliya, Israel.
Who is the COO & President of Revium Rx?
Inna Martin serves as the COO & President of Revium Rx.
Who is the CEO of Revium Rx?
David Akunis is the CEO of Revium Rx.
What is Revium Rx's current funding stage?
Revium Rx is currently in the Pre-Funding stage.
Does Revium Rx hold any patents?
Yes, Revium Rx holds one patent.

Team · 12

Amir Avraham
CEO
Shlomi Schwartzblat
Chairman of the Board
Igor Bluvstein
CFO
Ohad Rosenzweig
VP R&D
Dr Galit Levin
Senior R&D Director
Dr. Valeria Povolotsky
Partnering Advisor
Bernard Bartal
Director
Yoram Druker
Director
Matti Munk
Director
Prof. Allon E. Moses
Scientific Advisory Board Member
Prof. Itzhak Haviv
Scientific Advisory Board Member
Prof. Yechezkel Barenholz
Scientific Advisory Board Member

Sectors & technology

Primary sector
Biotechnology
Technologies
Target customers
Business model
Biopharmaceutical Development

Highlights

1 PatentsVerified

Tags

cancer-therapytherapeuticsimmunotherapydrug-deliverypharmaceuticals
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitereviumrx.com
LinkedInlinkedin.com/company/106169093

Identifiers & details

Legal nameRevium Rx
Former namesRevium Recovery Inc.
Founded1997-1
Employees (exact)5

Radar intelligence

Web history (Wayback)

Domainreviumrx.com

Certificate / subdomain footprint

Subdomains2

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)516211141
Statusפעילה
Corp typeישראלית חברה פרטית
Incorporated2020-06-22
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)no
Last annual report2024
Active charges / liens0
Registry events0
Registered addressהמנופים 10 הרצליה